Colin Reisner, MD
SVP & Head of Late RIA, R&D BioPharmaceuticals
Dr. Colin Reisner is Senior Vice President and Head of Late Stage RIA (Respiratory, Inflammation & Autoimmunity), BioPharmaceuticals R&D, AstraZeneca. He is an innovative leader with more than 20 years of international experience at top-tier companies, having previously workred at Boehringer Ingelheim, GSK and Novartis. Colin has extensive experience in both large and small companies, and was formerly both CMO and CEO of Pearl Therapeutics. In his current role he is actively involved in all late stage clinical programs in Late Stage RIA, including the inhaled, oral and biologics programs for AstraZeneca’s extensive asthma and COPD portfolio, the anti-RSV antibody program, and the Anifrolumab program for SLE.
Colin received his medical school training (MBBCH degree) from the University of Witwatersrand, Johannesburg, South Africa. He received specialist training in internal medicine at a Yale affiliated program, followed by sub-specialty training in Allergy Immunology at National Jewish in Denver, CO. He previously held adjunct faculty positions at Yale and at Duke University. He has published extensively, and is a fellow of the American College of Chest Physicians, a Fellow of the American Academy of Allergy Asthma & Immunology, is an active member of ATS and serves on the Drug/Device Discovery and Development Committee of the ATS.